Clinical trial NCT05505162: Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.
Official title: An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-Child-Bearing Potential
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Female Participants
Keywords: Ethinyl estradiol
Levonorgestrel
Zibotentan
Chronic Kidney Disease
Non-Child-Bearing Potential
Drug-drug interaction
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Parexel
First posted: 2022-08-17
Enrollment: 24
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when administered alone and in combination with multiple oral doses of zibotentan.

Detailed description: This is an open-label, single-sequence study conducted at a single study center.

The study will comprise of the following:

* A Screening Period (Visit 1) of maximum 28 days (Day -28 to Day -2).
* Treatment Period 1/Day 1 to Day 5 (in-house stay): Participants will check in at the clinical unit on Day -1 and will be resident at the clinical unit until Day 6.
* Treatment Period 2/Day 6 to Day 14 (home): Outpatient period.
* Treatment Period 3/Day 15 to Day 20 (in-house stay): On the evening of Day 14, the participants will check in at the clinical unit and will be resident at the clinical unit until Day 20.
* A follow-up visit (Day 27) will be conducted 7 days (±2 days) after the last PK sample collection (120 hours post-dose \[Day 20\]).

Participants will receive two tablets of EE/LNG on days 1 and 15 and 2 capsules of zibotentan on days 6-19.

Eligibility criteria: Inclusion Criteria:

* Provision of signed and dated, written informed consent prior to any study specific procedures.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the protocol.
* Healthy female participants aged 35 to 75 years (inclusive) at Day -1 with suitable veins for cannulation or repeated venipuncture.
* Females must have a negative pregnancy test at screening and within 24 hours prior to dosing with EE/LNG on Day 1 and Day 15, must not be lactating and must be of non childbearing potential, confirmed at screening by fulfilling one of the following criteria:

  (i) Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the postmenopausal range \[FSH \> 40 mIU/mL\].

(ii) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

* Have a body mass index (BMI) between 18.5 and 35 kg/m2 inclusive at Day -1.

Exclusion Criteria:

* History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. Clinically significant diseases or disorders also include, but are not limited to:

  (i) Undiagnosed abnormal uterine bleeding, (ii) Current diagnosis of, or history of breast cancer, which may be hormone sensitive, (iii) Liver tumors, benign or malignant, or liver disease. Acute viral hepatitis, or severe (decompensated) cirrhosis or use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alanine aminotransferase (ALT) elevations.
* Sex hormone therapy within 1 month before study.
* Current diagnosis or history of arterial or venous thrombosis (eg, deep vein thrombosis (DVT), pulmonary embolism (PE)), or known heredity risk factors (eg, activated protein C resistance), or coronary artery disease.
* Have inherited or acquired hypercoagulopathy.
* Participants treated with strong or moderate Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 3 months or longer (5 half-lives) prior to first administration of IMP in this study.
* History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* Any laboratory values with the following deviations:

  (i) Alanine aminotransferase \> Upper limit of normal (ULN) (ii) Aspartate aminotransferase \> ULN (iii) estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 (iv) Creatinine \> 1.5 ULN (v) White blood cell count \< 3.5 x 109/L (vi) Hemoglobin \< lower limit of normal (LLN)
* Prolonged QT interval (QTcF \> 470 ms) on ECG at check in into the clinical unit on Day 1 of Treatment Period 1, known congenital long QT syndrome or history of QT prolongation associated with other medications.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to zibotentan.
* Participants who have received zibotentan within 1 month prior to Day 1 dosing.
* Any of the following signs or confirmation of COVID-19 infection:

  (i) Positive COVID-19 test result on check in into the clinical unit on Day -1 and on Day 14.

(ii) Clinical signs and symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnoea, sore throat, and fatigue) on check in into the clinical unit on Day 1.

(iii) Previously hospitalized with COVID-19 infection within the last 3 months prior to the screening visit.

Primary outcomes:
measure: Area under plasma concentration time curve from zero to infinity (AUCinf)
timeFrame: Day 1 and Day 15
measure: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
timeFrame: Day 1 and Day 15
measure: Maximum observed plasma (peak) drug concentration (Cmax)
timeFrame: Day 1 and Day 15
measure: Terminal elimination half-life (t1/2λz)
timeFrame: Day 1 and Day 15
measure: Time to reach maximum observed concentration (tmax)
timeFrame: Day 1 and Day 15
measure: Apparent total body clearance of drug from plasma (CL/F)
timeFrame: Day 1 and Day 15
measure: Apparent volume of distribution based on terminal phase (Vz/F)
timeFrame: Day 1 and Day 15
Secondary outcomes:
measure: Area under plasma concentration-time curve in the dose interval (AUCtau)
timeFrame: Day 15
measure: Maximum observed plasma (peak) drug concentration (Cmax)
timeFrame: Day 15
measure: Time to reach maximum observed concentration (tmax)
timeFrame: Day 15
measure: Number of participants with adverse events
timeFrame: Until Follow up visit (7 days +/-2 days after last PK sample)
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Research Site
state: Maryland
Study officials:
References: